Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Guotai Wang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5129034881. Sources: OpenAlex.

Their work

Papers
5 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 5

  1. Resveratrol inhibits pancreatic cancer progression via the ING5 signaling pathway. Co-author DOI 10.1038/s41598-026-44216-x↗
  2. Resveratrol inhibits pancreatic cancer proliferation and metastasis by depleting senescent tumor-associated fibroblasts. First author DOI 10.4251/wjgo.v16.i9.3980↗
  3. Correction to: Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. First author DOI 10.1007/s00210-023-02499-1↗
  4. Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. First author DOI 10.1007/s00210-022-02203-9↗
  5. Resveratrol Exerts Antitumor Effects on Pancreatic Cancer by Inhibiting Notch Signaling Induced by Chronic Stress Co-author DOI 10.21203/rs.3.rs-2305575/v1↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. He Jiang · 4 shared papers, 2022–2026 · strength 1.01
  2. Zheng Wang · 3 shared papers, 2022–2024 · strength 0.62
  3. MA Qing-yong · 2 shared papers, 2022–2024 · strength 0.45
  4. Qingyong Ma · 2 shared papers, 2022–2023 · strength 0.34
  5. Ying Xiao · 2 shared papers, 2022–2023 · strength 0.34
  6. Jingtao Gu · 2 shared papers, 2022–2023 · strength 0.34
  7. Pengli Wang · 2 shared papers, 2022 · strength 0.33
  8. Zhenhua Ma · 1 shared paper, 2024 · strength 0.28
  9. Wanxing Duan · 1 shared paper, 2022 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.